Equities analysts forecast that Enanta Pharmaceuticals Inc (NASDAQ:ENTA) will report earnings per share of ($0.04) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Enanta Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.27) and the highest estimate coming in at $0.11. Enanta Pharmaceuticals posted earnings per share of $0.97 during the same quarter last year, which would suggest a negative year over year growth rate of 104.1%. The company is scheduled to report its next quarterly earnings results on Tuesday, August 6th.
According to Zacks, analysts expect that Enanta Pharmaceuticals will report full year earnings of $1.53 per share for the current financial year, with EPS estimates ranging from $0.81 to $2.00. For the next fiscal year, analysts expect that the firm will post earnings of ($0.60) per share, with EPS estimates ranging from ($1.64) to $0.06. Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Enanta Pharmaceuticals.
Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported $0.20 EPS for the quarter, beating the consensus estimate of ($0.09) by $0.29. Enanta Pharmaceuticals had a return on equity of 19.25% and a net margin of 33.28%. The company had revenue of $39.60 million for the quarter, compared to analysts’ expectations of $40.92 million. During the same period last year, the firm posted $0.61 earnings per share. Enanta Pharmaceuticals’s revenue was down 10.0% compared to the same quarter last year.
Several equities research analysts recently commented on ENTA shares. BidaskClub cut Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, May 1st. Zacks Investment Research cut Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, January 25th. Finally, Berenberg Bank raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and increased their price objective for the company from $80.00 to $120.00 in a research report on Tuesday, April 23rd. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Enanta Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $114.40.
Shares of Enanta Pharmaceuticals stock traded up $0.68 during trading on Tuesday, hitting $90.96. 136,899 shares of the company’s stock traded hands, compared to its average volume of 235,374. Enanta Pharmaceuticals has a 1 year low of $64.08 and a 1 year high of $127.77. The stock has a market capitalization of $1.78 billion, a PE ratio of 26.14 and a beta of 1.30.
In other Enanta Pharmaceuticals news, VP Yat Sun Or sold 10,000 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $103.53, for a total value of $1,035,300.00. Following the transaction, the vice president now directly owns 304,763 shares of the company’s stock, valued at $31,552,113.39. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bruce L. A. Carter sold 1,546 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $99.16, for a total value of $153,301.36. Following the completion of the transaction, the director now directly owns 1,546 shares in the company, valued at $153,301.36. The disclosure for this sale can be found here. Insiders sold 20,826 shares of company stock worth $2,150,473 over the last three months. Insiders own 11.35% of the company’s stock.
A number of large investors have recently made changes to their positions in the business. Bank of New York Mellon Corp boosted its stake in shares of Enanta Pharmaceuticals by 4.0% during the third quarter. Bank of New York Mellon Corp now owns 256,446 shares of the biotechnology company’s stock valued at $21,917,000 after purchasing an additional 9,799 shares during the period. Legal & General Group Plc raised its holdings in Enanta Pharmaceuticals by 29.2% in the third quarter. Legal & General Group Plc now owns 37,415 shares of the biotechnology company’s stock worth $3,232,000 after purchasing an additional 8,465 shares in the last quarter. Vanguard Group Inc. raised its holdings in Enanta Pharmaceuticals by 30.1% in the third quarter. Vanguard Group Inc. now owns 1,426,791 shares of the biotechnology company’s stock worth $121,934,000 after purchasing an additional 330,374 shares in the last quarter. Vanguard Group Inc raised its holdings in Enanta Pharmaceuticals by 30.1% in the third quarter. Vanguard Group Inc now owns 1,426,791 shares of the biotechnology company’s stock worth $121,934,000 after purchasing an additional 330,374 shares in the last quarter. Finally, State of Alaska Department of Revenue raised its holdings in Enanta Pharmaceuticals by 3.9% in the fourth quarter. State of Alaska Department of Revenue now owns 5,282 shares of the biotechnology company’s stock worth $374,000 after purchasing an additional 200 shares in the last quarter. 86.86% of the stock is currently owned by institutional investors and hedge funds.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.
Read More: Intrinsic Value
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.